GLUE β€” MONTE ROSA THERAPEUTICS INC

Ownership history in MACKENZIE FINANCIAL CORP  Β·  2 quarters on record

This page tracks every 13F SEC filing in which MACKENZIE FINANCIAL CORP reported a position in MONTE ROSA THERAPEUTICS INC (GLUE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

% of Fund (quarterly)    GLUE price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 2 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 77,635 β€” 0% 0.00% $575K $7.41
2025 Q2 INITIATED 77,635 β€” β€” 0.00% $350K $4.51

🏒 Other funds also holding GLUE

As of 2025 Q4 β€” sorted by position size

Versant Venture Management, LLC 3Y 7Y 45.49% NEA Management Company, LLC 3Y 7Y 6.15% Aisling Capital Management LP 3Y 7Y 4.82% TCG Crossover Management, LLC 3Y 2.4% SILVERARC CAPITAL MANAGEMENT, LLC 3Y 2.24% MPM BioImpact LLC 3Y 2.11% BVF INC/IL 3Y 7Y 2.02% SUVRETTA CAPITAL MANAGEMENT, LLC 3Y 7Y 1.08% Rangeley Capital, LLC 0.88% Parkwood LLC 3Y 7Y 0.86%
← Back to MACKENZIE FINANCIAL CORP Holdings